SLC5A2 and type 2 diabetes mellitus: Protective effects on the impaired renal function in T2DM were demonstrated in cultured cells, animal models, and patient studies for SGLT2 inhibitors canagliflozin, dapagliflozin, empagliflozin, irtugliflozin, and sotagliflozin.